Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.

  title={Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.},
  author={Peichen Pan and Mingyun Shen and Huidong Yu and Youyong Li and Dan Li and Tingjun Hou},
  journal={Drug discovery today},
  volume={18 23-24},
Rho-associated protein kinases (ROCK1 and ROCK2) belong to the AGC family of serine-threonine kinases, and regulate a wide range of fundamental cell functions. Inhibition of ROCK has been proven to be of potential therapeutic benefit for a variety of diseases. In this review, the structures and therapeutic importance of ROCK are discussed briefly. Then, the recent status of the development of ROCK inhibitors is also summarized. Our review offers a foundation outline from which strategies to… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 76 references

24h IOP control by subchronic AMA0076 administration


Rho-kinase I inhibitors

J. Biotechnol • 2013

Synthesis and biological evaluation of urea derivatives as highly potent and selective Rho kinase inhibitors

Y Yin
J. Med. Chem • 2013

Topical application of AMA0076, a locally acting rho kinase (ROCK) inhibitor, results in a robust IOP control in Dutch Belted Rabbits

S Van de Velde
Acta Ophthalmologica 90, • 2012

Similar Papers

Loading similar papers…